Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock Has Consensus Price Target of $87.38 According to Brokerages

Key Points

• Analyst sentiment is moderately bullish: Ten brokerages rate Kiniksa Pharmaceuticals International a consensus “Moderate Buy,” with eight buys and two holds. The average 12-month price target is $87.38, above the reported share price of $75.34.
• Kiniksa reported quarterly EPS of $0.30, in line with estimates, while revenue of $243.6 million exceeded expectations of $226.49 million. Analysts expect full-year EPS of approximately $1.37.
• Company insiders recently sold shares, while insiders and institutional investors retain significant ownership stakes of 51.98% and 53.95%, respectively.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $87.38.

A number of equities research analysts have weighed in on KNSA shares. Wells Fargo & Company raised their target price on Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the company an "overweight" rating in a report on Monday, July 13th. Weiss Ratings downgraded Kiniksa Pharmaceuticals International from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Thursday, August 13th. Zacks Research lowered Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 30th. JPMorgan Chase & Co. lifted their target price on Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the company an "overweight" rating in a research report on Wednesday, July 29th. Finally, Canaccord Genuity Group boosted their target price on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ:KNSA opened at $75.34 on Friday. The company has a market capitalization of $5.88 billion, a P/E ratio of 77.67 and a beta of 0.09. Kiniksa Pharmaceuticals International has a 1 year low of $35.20 and a 1 year high of $82.94. The business's 50 day simple moving average is $75.82 and its 200 day simple moving average is $60.55.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The business had revenue of $243.60 million for the quarter, compared to analysts' expectations of $226.49 million. On average, sell-side analysts anticipate that Kiniksa Pharmaceuticals International will post 1.37 EPS for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals International

In related news, Director G. Bradley Cole sold 3,673 shares of the company's stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total transaction of $299,092.39. Following the completion of the transaction, the director directly owned 11,672 shares in the company, valued at $950,450.96. This represents a 23.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Michael Megna sold 4,600 shares of the stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total transaction of $369,380.00. Following the completion of the transaction, the chief accounting officer directly owned 29,062 shares of the company's stock, valued at approximately $2,333,678.60. The trade was a 13.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 51.98% of the company's stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Hedge funds have recently modified their holdings of the company. Allworth Financial LP grew its position in Kiniksa Pharmaceuticals International by 42.0% in the 2nd quarter. Allworth Financial LP now owns 453 shares of the company's stock valued at $29,000 after purchasing an additional 134 shares during the period. Arizona State Retirement System increased its stake in Kiniksa Pharmaceuticals International by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 10,132 shares of the company's stock valued at $648,000 after purchasing an additional 209 shares in the last quarter. First Trust Advisors LP raised its holdings in Kiniksa Pharmaceuticals International by 3.1% during the first quarter. First Trust Advisors LP now owns 9,876 shares of the company's stock worth $476,000 after buying an additional 293 shares during the last quarter. Nykredit A S acquired a new position in Kiniksa Pharmaceuticals International during the second quarter worth $34,000. Finally, KBC Group NV bought a new position in shares of Kiniksa Pharmaceuticals International in the first quarter valued at $34,000. Institutional investors and hedge funds own 53.95% of the company's stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc NASDAQ: KNSA is a biopharmaceutical company focused on discovering, developing and commercializing therapies for patients with debilitating diseases, particularly conditions involving the immune system and inflammation. The company concentrates on areas of significant unmet medical need and uses biologic medicines and other targeted approaches in its research and development programs.

Kiniksa's principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.